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Randomized Control Trial (RCT) is considered the most accurate method in 
evaluating the effectiveness of a treatment. In 1996, in order to improve the quality of 
published studies, the Consolidated Standards for Reporting Trials (CONSORT) 
statement was published. It was the result of a cooperation of scientists and 
publishers aiming to provide authors a guideline. 
I searched Pub Med database for RCTs published from 2011 to 2016, for treatment 
on Non-Hodgkin’s lymphoma (NHL). From the 183 studies found in Pub Med, eligible 
for further analysis were 74. Based on the evaluation the compliance with the 
CONSORT statement remains very low. Authors still avoid reporting important details 
about the design of their trials, such as randomization strategy, the calculation of the 
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Randomized Control Trials (RCTs) are considered the gold standard in scientific 
research and the most accurate methods to determine if there is a cause-effect 
relation between treatment and outcome as well as the efficacy of the treatment 
(Kober et al., 2006).  Participants are randomly assigned to either a control group 
(placebo or standard method of treatment) or to one of the experimental groups. 
Randomization process of patients without intervention of researchers minimizes 
selection bias. Therefore, on average the characteristics of the participants will be 
similar among the different groups without affecting the results.  A well designed and 
executed RCT can result to more reliable and transparent evidence. Over the last 
decades, RCTs publications have overrun biomedical journals and the need for an 
evaluation guideline arose.  
On 1996, a group of scientists and editors published the CONSORT (Consolidated 
Standards of Reporting Trials) statement aiming to help authors improve the 
reporting quality of RCTs reports. CONSORT statement was revised again on 2001 
and 2010 in light of new empirical evidence and experience. The use of CONSORT 
statement is associated with the improvement of the reporting quality of RCTs 
(Schulz et al. 2010) However, according to similar evaluation research the 
compliance of RCTs with the CONSORT statement has increased but still there is no 
great improvement (Ziogas-Zintzaras 2009, Kober et al. 2006). 
Non-Hodgkin’s Lymphoma (NHL) is the most common cancer of lymphatic system, a 
part of the immune system. It consists of a group of several closely related cancers.  
The World Health Organization (WHO) estimates that there are 61 distinct types of 
NHL. NHL can be divided in two major groups: 
 B-cell lymphoma that counts about 85% of annually cases. 
 T-cell (15% of cases). 
Another possible deviation is in indolent (slow-growing) and aggressive (fast 
growing). 
There are 4 possible stages of the disease depending on its extension: 
I. Early Stage: Cancer is found in a single lymph, an organ or in an area outside 
the lymph node. 
II. Locally Advanced Disease: Cancer is found in two or more lymph node 
regions on the one side of the diaphragm. 
III. Advanced Disease: Cancer on this stage is found in lymph nodes on both 
sides of the diaphragm. 
IV. Widespread disease: Cancer is spread in several parts of one or more 
organs or tissues or it can be found in the liver, blood and bone 
marrow. 
There are many treatment options depending on the stage of the disease, the 
age and health of the patient and prior therapies. Some options are the active 
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surveillance, also known as watchful waiting, chemotherapy, stem cell 
transplantation, radiation therapy or novel targeted agents. 
In the present study, a reporting quality analysis of RCTs from 2011 until 2016 will be 
conducted regarding the treatment of NHL. The items of the revised CONSORT 2010 
statement checklist will be used. 
2. METHODS 
2.1 DATA SOURCES AND RESEARCH STRATEGIES 
The Pub Med database was used to search for studies on RCTs for NHL treatments 
from 1/1/2011 to 31/12/216. The search criteria were “treatment” and “non-hodgkin’s 
lymphoma”. The filter of the article, the language and the species were “Randomized 
Control Trials”, “English” and “humans” respectively. 
2.2 ELIGIBILITY OF STUDIES 
A study is considered eligible for analysis when is in line with the following criteria. 
The participants have to be randomly assigned to at least two treatment arms. 
Patients should have any type of NHL and the aim of the study should be the 
treatment of NHL. RCTs about health quality, treatment of side effects or 
consolidation treatment were not included in the analysis. Moreover, studies 
comparing the results of previous publications were included only if these were 
RCTs. 
2.3 REPORTING ASSESSMENT TOOL AND EVALUATION ANALYSIS 
The revised CONSORT 2010 checklist (http://www.consort-statement.org) was used 
as an assessment tool for the studies. We used the 22-item checklist and the 
answers were based on the CONSORT 2010 Explanation and Elaboration that is 
available online from the CONSORT statement web page.  
The evaluation analysis is based on the number of CONSORT statement items that 
are reported on the study. For each of the items in the list only two possible answers 
were considered (positive or negative). If the item is reported and there is sufficient 
elaboration then I conclude that it is present and the answer is positive. On the other 
hand if an item is not mentioned, even if it is carried out in the trial, or there are no 
necessary details presented in the study, then the answer is negative. For example, 
the CONSORT item 7:”How sample size was determined” , in order to have a 
positive answer the study should include, apart from the number of the participants in 
each arm,  details on how it was calculated such as estimated outcomes in each 
group, the type II error level, statistical power etc (CONSORT E&E).  Moreover, it is 
essential each of these items to be reported on the specific part of the study as 
indicated by the CONSORT statement. For instance, Consort item 14 “Dates defining 
the periods of recruitment and follow-up” if mentioned in the Results the answer is 
positive. But if it is mentioned in the METHODS then it is considered non-reported in 
the study. Last but not least, items reported on Appendix or Supplementary Data 
were not taken into consideration. For the evaluation of the studies Microsoft-excel 
2010 software was used.  
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Τhe search on Pub Med database retrieved 183 studies. From these, 92 studies, out 
of the initial selected ones,  were excluded after screening  the titles due to their 
irrelevant subject (quality of life, exercise, Hodgkin’s lymphoma etch). After reading 
the abstracts of the 93 remaining studies I had to exclude 9 studies, 1 was retracted, 
1 was not in English and 7 were irrelevant to this topic. The remaining 82 studies 
were analytically reviewed and 8 studies were left out mainly because of no 
randomization or because they were not in English or access was not allowed. 
 
Flow Chart of search strategy  
Table 1 summarizes the percentage of each item in the analyzed studies. In general, 
we can conclude that the items in the Results part are more in line with the 
CONSORT statement comparing to the items in the Method part. This can indicate 
that researchers are more interested in presenting their conclusive results than trying 
illustrating the design of the trials. 
Almost all the studies (72 out of 74, 97.3%) mentioned either on the title or in the 
abstract that it was a randomized trial or that the participants were randomized in 
treatment groups. As we expect all studies present sufficient scientific background 
references justifying the need for a new trial (100%) in the introduction.  
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Table 1. Percentage of compliance with CONSORT statement 
 
 1. Randomized in title/abstract 97,30% 72 
 
2. Scientific background in 







3. Eligibility criteria for 
participants 91,89% 69 
4. Precise details of the 
interventions in each arm 90,54% 67 
5. Objectives 98,65% 73 
6. End-points 97,30% 72 
7. Sample size 71,62% 53 
8. Method of randomization 
(sequence generation) 50,00% 37 
9. Allocation concealment 13,51% 10 
10. Implementation of 
randomization 27,03% 20 
11. Blinding (masking) 9,46% 7 






13. Participant flow 70,27% 52 
14. a Recruitment 63,51% 47 
14.b Follow Up 79,73% 59 
15. Baseline data 94,59% 70 
16. Numbers analyzed 78,38% 58 
17.a Outcomes 100,00% 74 
17.b estimation 94,59% 70 
18. Ancillary analyses 
 
70,27% 52 








20. Interpretation 85,14% 63 
21. Generalisability 64,86% 48 
22. Overall evidence 66,22% 49 
 
Also, they clearly separated the primary, of great importance, from the secondary 
endpoints of the study. 
Intervention applied in each treatment arm was sufficiently described in 90.54% (67) 
of the studies. Furthermore, 93.24% of the studies presented extensive information 
on the selection criteria of the participants for the trial and some of them presented 
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also exclusion criteria. The same percentage of studies (93.24%) described the 
statistical methods that were used for the analysis and the comparison of the primary 
and secondary outcomes of the study.  
On the contrary, only 53 out of 74 (71.64 %) studies sufficiently demonstrated how 
the sample size was calculated. All studies reported the needed number of 
participants in each group but not all of them presented the level of statistical 
significance, the type I and type II errors etc. 
The items that gathered the lowest percentages were those describing the 
Randomization and Blinding strategy. Only 7 out of 74 studies were clear on which 
blinding procedure was used and on who was blinded. In most of the studies, authors 
did not clearly report which group was blinded or how this happened. Last but not 
least, only in half (50%, 37 out of 74) studies the method of randomization was 
explained. They may refer to the ratio that was used for the randomization process 
but no further details on how it was implemented and even less studies, only 10 out 
of 74 (9.46%) explained how the allocation concealment was secured. 
CONSORT statement strongly recommends authors to include a participants’ flow 
diagram that will visualize how participants are allocated in treatment groups, how 
many were eliminated and why, in each phase of the trial. From the 74 studies 
analyzed only 53 (70.27%) included a flow diagram in the results part while some of 
the remaining presented it in the Appendix or Supplementary Data. Even less were 
the studies that reported sufficient details on participants’ recruitment (47(63.51%) 
out of 74) in the results section. Those provided clear details about the follow-up 
period were 59 out of 74 (79.73%). They stated either the specific date that the 
follow-up ended for all participants or specified the period that the follow-up lasted 
after the randomization of the participants.  
In order to evaluate the results of a study and the significance of them, it is important 
the treatment groups to have similar baseline characteristics and the only difference 
should be the treatment. Knowing the characteristics of the groups would be 
necessary for clinicians to evaluate for which patients the treatment is suitable and 
also for the right interpretation of the results. Based on my evaluation, 94.59% of the 
studies analyzed included a detailed table that presented the Baseline demographic 
characteristics of the participants.  
It is very important for the analysis to demonstrate information about the number of 
participants in each group and to present all changes that may occur due to loss of 
participants, wrong allocation or randomization of ineligible participants. Authors 
should be clear on what was the population of patients that was used for the analysis 
and this was clear only for 58 of the studies I analyzed and only 30 of them reported 
that the analysis followed the intention-to-treat strategy.  
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On the other hand, all of the studies demonstrated results for their preplanned 
primary and secondary outcomes both in details and in tables that presented the 
confidence interval. Also they all included a detailed comparison for the results of the 
groups. Of the 74 analyzed studies 52 (70.2%) included results for multiple ancillary 
analysis of the data, allowing them to identify the analyzed subgroups and the reason 
of this analysis. It is crucial for a tested treatment to report not only the results for the 
outcome but also the adverse events that were observed during the trial. In my 
analysis 63 out of 74 studies reported sufficient information about the adverse events 
recorded during the treatment. 
The 85.14% (63) of the studies interpreted the results by presenting both strong and 
weak parts, such as limitations in the design, treatment, participants’ characteristics 
etc. A clinical trial is useful when the results can be generalized to similar cases too. 
When the characteristics of the participants are well balanced and well described, the 
trial was well designed and well executed and the results are carefully analyzed and 
presented then it is easier for clinicians to interpret them and follow them in similar 
cases. Consequently, the results of 64.86% of the studies can be generalized. The 
overall evidence was judged sufficient based on evaluating the presented and the 
missing items and on my personal point of view and is equal to 66.22%. 
The average CONSORT compliance reached 71.28% (37.5% - 95.83%). 43 studies 
had  a score of more than 75% compliance, 11 out of 74 more than 90% and 10 had 
a score lower than 60%.  
 
4. DISCUSSION   
The aim of this study was to evaluate the reporting quality of RCTs on treatment of 
NHL. The results indicate that the desired quality is not yet achieved and the overall 
level of compliance with the CONSORT statement remains low. This is in line with 
similar results found after evaluating RTCs from different fields of medical science 
(Rikos et al.,2016, Huang et al., 2015). 
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and treatment, (Herbrecht et al., 2013). As I have already stated, there seems to be a 
preference in reporting more details on the Results than the Methods for most of the 
authors. This may imply that they are more interested in presenting the results rather 
than explaining in details the design of their research. 
The two major weaknesses of this study are the lack of any medical background 
studies and the fact that there was not a second reviewer for the evaluation. The 
approach was based on a more practical method. Initially, I tried to identify the items 
of the CONSORT statement in the studies and then to evaluate them. I used as a 
guideline the CONSORT 2010 Explanation and Elaboration. However, my incomplete   
knowledge in medical made it difficult sometimes to perform an evaluation for some 
of the items such as whether or not the authors gave sufficient information on the 
treatment that was followed in each treatment arm or if the description of the eligibility 
criteria was sufficient.  On the other hand, this can lead to a more unbiased 
evaluation of a study. 
Further research is needed in the evaluation of RCTs on treatment of NHL as well as 
in the contribution of the CONSORT statement regarding its attribution in improving 
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